impact of Allopurinol use on one-year outcome of patients with acute anterior myocardial infarction undergoing PPCI

In this clinical trial (IRCT20140512017666N2), 170 patients with anterior STEMI at Shahid Madani Hospital in Tabriz undergoing successful primary angioplasty within 12 hours of
the onset of symptoms were included in the study. Patients were randomly divided into two groups of 85 patients receiving allopurinol (intervention group) and receiving the standard protocol (control group). The intervention group received 300 mg of allopurinol before angioplasty and then 100 mg daily for one month after angioplasty. The two groups were then evaluated for in-hospital MACE and followed up for one year for clinical outcomes. Clinical outcomes studied included mortality, stroke, and heart failure. Telephone calls were made to patients in 1-6-12 months.
The results of the present study showed that allopurinol administration had no effect on the clinical outcome and one-year complications of patients with STEMI who underwent primary angioplasty.

在本项临床研究中（IRCT20140512017666N2），纳入了在伊朗大不里士的沙希德·马丹尼医院接受成功初级血管成形术的前壁ST段抬高型心肌梗死（STEMI）的170名患者。这些患者在症状出现后12小时内接受了血管成形术。患者被随机分为两组，每组85名，分别接受别嘌醇（干预组）和标准方案（对照组）治疗。干预组患者在血管成形术前服用300毫克别嘌醇，并在血管成形术后的一个月内每日服用100毫克。随后，两组患者在院内的主要不良心血管事件（MACE）方面进行了评估，并随访一年以观察临床结果。研究涉及的临床结果包括死亡率、中风和心力衰竭。在1、6和12个月时，对患者的电话随访得以实施。本研究结果显示，别嘌醇的给予对接受初级血管成形术的STEMI患者的临床结果和一年的并发症并无显著影响。